Nimodipina Labesfal (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels on the smooth muscle of cerebral arteries. This inhibition reduces calcium entry into the cells, causing the vessels to relax and dilate. The resulting increase in cerebral blood flow and the neuroprotective properties of the drug help mitigate the consequences of vasospasm after hemorrhage.

The exact dose and dosing schedule of Nimodipina Labesfal are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Healthcare professionals follow established guidelines and adjust therapy as needed; patients should not alter the dose without medical advice.

The safety of nimodipine in pregnancy and lactation has not been definitively established. It is classified as a pregnancy category with unknown risk, so the drug should only be used if the potential benefit justifies the possible risk to the fetus. Breastfeeding mothers should discuss alternatives with their healthcare provider.

To request Nimodipina Labesfal, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Nimodipine is the only calcium channel blocker specifically approved for preventing cerebral vasospasm after subarachnoid hemorrhage. Other agents, such as clazosentan or endothelin‑receptor antagonists, target different pathways and may be used in research settings or specific protocols. Nimodipine’s oral route and well‑characterized safety profile make it a first‑line choice in most clinical guidelines.

Store Nimodipina Labesfal at temperatures below 25 °C (77 °F). Keep the product in its original container, protect it from moisture, excessive heat, and direct sunlight. Do not store in a refrigerator or freezer unless the packaging specifically indicates a need for cold‑chain storage.

Nimodipina Labesfal is administered orally, typically as a tablet or capsule taken with water. The medication should be swallowed whole and not chewed or crushed unless directed by a healthcare professional. Administration timing (e.g., with or without food) follows the prescriber’s instructions to maintain consistent blood levels.

The most serious risks include severe hypotension that can lead to syncope or shock, myocardial infarction in susceptible patients, and rare cases of hepatic dysfunction or severe allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of these events, especially during the initiation of therapy.

Nimodipina Labesfal is contraindicated in patients with known hypersensitivity to nimodipine or any component of the formulation. It should also be avoided in individuals with severe uncontrolled hypotension, recent myocardial infarction, or those taking interacting medications that could cause dangerous blood‑pressure drops without appropriate medical supervision.